These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 18654214)
1. The perils of pre-emptive regulation. Monica JC; Heintz ME; Lewis PT Nat Nanotechnol; 2007 Feb; 2(2):68-70. PubMed ID: 18654214 [No Abstract] [Full Text] [Related]
2. Science and regulation. FDA's approach to regulation of products of nanotechnology. Hamburg MA Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845 [No Abstract] [Full Text] [Related]
3. [Are nanoparticles a new class of environmental toxin?]. Masse R; Boudène C Bull Acad Natl Med; 2011 Dec; 195(9):2037-43. PubMed ID: 22930867 [TBL] [Abstract][Full Text] [Related]
4. Necessity and approach to integrated nanomaterial legislation and governance. Wang J; Gerlach JD; Savage N; Cobb GP Sci Total Environ; 2013 Jan; 442():56-62. PubMed ID: 23178764 [TBL] [Abstract][Full Text] [Related]
5. Are environmental regulations keeping up with innovation? A case study of the nanotechnology industry. Fairbrother A; Fairbrother JR Ecotoxicol Environ Saf; 2009 Jul; 72(5):1327-30. PubMed ID: 19423165 [TBL] [Abstract][Full Text] [Related]
6. Nanotechnology-related environment, health, and safety research: examining the national strategy. Schmidt CW Environ Health Perspect; 2009 Apr; 117(4):A158-61. PubMed ID: 19440480 [No Abstract] [Full Text] [Related]
11. Hasta la vista--for now. Will Schwarzenegger's move terminate policy plans? Benko LB Mod Healthc; 2003 Dec; 33(49):10. PubMed ID: 14712593 [No Abstract] [Full Text] [Related]
12. FDA to steer nanotech. Fox JL Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060 [No Abstract] [Full Text] [Related]
13. In response: regulatory risk assessment and landscape ecotoxicology--a governmental perspective. Wendt-Rasch L; Poulsen V; Duquesne S Environ Toxicol Chem; 2014 Jun; 33(6):1196-7. PubMed ID: 24838920 [No Abstract] [Full Text] [Related]
14. The US must help set international standards for nanotechnology. Murashov V; Howard J Nat Nanotechnol; 2008 Nov; 3(11):635-6. PubMed ID: 18989319 [No Abstract] [Full Text] [Related]
15. [Drug surveillance. Its present status, hopes for its future]. Bechtel P Gastroenterol Clin Biol; 1984 Oct; 8(10):702-3. PubMed ID: 6526225 [No Abstract] [Full Text] [Related]
16. [The future of pharmacologic surveillance in Spain: the need to join efforts]. Soto J Med Clin (Barc); 1996 Sep; 107(10):375-6. PubMed ID: 9036241 [No Abstract] [Full Text] [Related]
17. The challenges of regulating stem cell-based products. von Tigerstrom BJ Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047 [TBL] [Abstract][Full Text] [Related]
18. [REVIDAL-GERDA: organization and collaboration with pharmacovigilance]. Vigan M Therapie; 2002; 57(3):263-4. PubMed ID: 12422539 [No Abstract] [Full Text] [Related]
19. The Fidelis recall: how much pressure can the ICD world bear? Cannom DS; Fisher J Pacing Clin Electrophysiol; 2008 Oct; 31(10):1233-5. PubMed ID: 18811800 [No Abstract] [Full Text] [Related]
20. Echocardiographer as patient advocate: lessons from the contrast debate. Ryan T J Am Soc Echocardiogr; 2008 Mar; 21(3):A29. PubMed ID: 18314045 [No Abstract] [Full Text] [Related] [Next] [New Search]